Alterity Therapeutics Limited PRNAF

PRNAF Company Overview

Alterity Therapeutics Limited is an Australian biotechnology company focused on developing therapies for neurodegenerative diseases associated with abnormal iron accumulation and protein aggregation. The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, with a primary emphasis on rare neurodegenerative disorders. Alterity’s lead development programs target diseases such as Multiple System Atrophy (MSA) and other movement disorders where dysregulated iron biology is believed to contribute to neuronal degeneration.

The company’s principal revenue and enterprise value drivers are tied to clinical-stage drug development, intellectual property, and research partnerships rather than commercial product sales. Alterity is best known for its small-molecule therapeutics platform designed to redistribute excess iron in the brain and reduce toxic protein aggregation. Its lead candidate, ATH434, has been the centerpiece of the company’s clinical development strategy. Formerly known as Prana Biotechnology Limited, the company rebranded to Alterity Therapeutics to reflect its strategic transition toward targeted neurodegenerative disease therapeutics and precision CNS drug development.